Beckman Coulter#s Automated Microplate System Provides High-Volume Laboratories with Unmatched Throughput for Donor Blood Testing

Food and Healthcare Press Releases Thursday January 31, 2019 08:55
BREA, California--31 Jan--PRNewswire/InfoQuest
  • The new PK7400 leverages Beckman Coulter's more than 30-year customer proven reliability, accuracy and workload capacity

Beckman Coulter, a global leader in the clinical diagnostics industry, announced today the launch of its next-generation fully automated microplate system for donor blood testing, the PK7400. Designed for use in blood donor centers, plasma centers and large reference laboratories, the new system offers the industry's highest throughput, processing the greatest volume of samples for a single analyzer in its class – up to 300 samples per hour.

"Customers have relied on our PK systems for more than 30 years to deliver the quality results and workload capacity they have come to expect from Beckman Coulter," said Puneet Sarin, senior vice president and general manager for Beckman Coulter's chemistry and immunoassay business. "We designed the PK7400 to further that legacy by providing donor laboratory professionals with the reliability and workflow they need to improve staff efficiency."

The new PK7400 system also provides the ability to test multiple assays in a single batch without affecting the throughput. The assay menu includes ABO blood grouping, Rh typing, weak D testing, red blood cell antigen screening as well as syphilis qualitative screening**. Backed by Beckman Coulter's PROService tool, the PK7400 also facilitates real-time monitoring that helps to improve laboratory system uptime and reduce service visits.

Beckman Coulter's commitment to moving healthcare forward includes providing laboratory professionals with superior workflow solutions to help minimize laboratory workload. The PK7400 was designed with specific workflow enhancements including easier-to-load supplies and improved visual instrument status. These research and development advancements reinforce Beckman Coulter's ongoing mission to bringing innovative solutions to the diagnostics industry.

For more information on the PK7400, visit
About Beckman Coulter Diagnostics

Beckman Coulter Diagnostics helps healthcare and laboratory professionals provide better patient care by delivering the accurate diagnostic information they need, when they need it. With a rich 80-year history, Beckman Coulter is a strong partner for healthcare organizations. Our scalable instruments, comprehensive diagnostic tests and business management services are trusted by hospitals, laboratories and other critical care settings around the world. We share in our customers' mission toward continuous improvement and quality patient care because we believe when efficiency and clinical outcomes are improved, patients benefit and we can move healthcare forward for every person.

*Product availability and regulatory status depends on country registration per applicable regulations.
**Not all assays are available in all markets.

(C) 2019 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Photo -
Logo -

Latest Press Release

Mallinckrodt Announces Interim Analysis Results for Therakos(R) Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease

-- Overall response rate exceeded specified study midpoint target (n=25); company elects to discontinue further patient enrollment as allowed by protocol -- Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceutical company, today announced...

Takeda, Microsoft and EURORDIS release report with action plan to help rare disease community shorten the diagnostic odyssey

- Global Commission's recommendations focus on three solution pathways that leverage technology to address key elements of the rare disease diagnostic odyssey - Rare diseases remain undiagnosed as patients struggle to navigate complex health systems to...

Pivotal Phase III Data for BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

- JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for patients with advanced renal cell...

ISABS เตรียมจัดการประชุมว่าด้วยการแพทย์ส่วนบุคคลที่โครเอเชีย พร้อมเชิญเจ้าของรางวัลโนเบลร่วมบรรยาย

International Society for Applied Biological Sciences (ISABS) ร่วมกับ Mayo Clinic และ St. Catherine Hospital เตรียมจัดการประชุม "ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine" ครั้งที่ 11...

ISABS: Personalized Medicine Conference With Nobel Laureates to Be Held in Split, Croatia

International Society for Applied Biological Sciences (ISABS), Mayo Clinic and St. Catherine Hospital are organizing "11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine"(

Related Topics